Characterization of Immune-response in Autoimmune Encephalitis and Paraneoplastic Neurological Syndromes

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorHospices Civils de Lyon

About this trial

Autoimmune encephalitis (AE) and paraneoplastic neurological syndromes (PNS) are rare neuroimmune syndromes with a wide range of clinical presentation but without pathognomonic clinical sign facilitating the diagnosis. A lot of differential diagnoses are possible such as neurodegenerative diseases or viral infections. Although rare the diagnosis of AE or PNS is essential because despite severe neurological symptoms, patients can be cured by appropriate immunotherapy. Autoantibodies highly specific of AE and PNS has been described in the serum and cerebrospinal fluid of the patients and can be used as biomarkers of the disease. Their presence can predict an autoimmune origin and in many cases a good prognosis after immunotherapy. However, if some autoantibodies are now well-characterized and industrial kits have been developed to detect them, in numerous cases of highly suspect AE or PNS no specific autoantibodies are identified leading frequently to an inappropriate treatment. Furthermore, as the mechanisms of AE and PNS is still unknown, treatments are not optimal and in some cases inefficient. There is no prognosis biomarker able to predict the patient's sensitivity to immunotherapy and there are only few clues to know how the immune system can provoke the neuropsychiatric symptoms observed in the patients.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patient with neurological disorder

Patient with antibodies or not in sera or CSF

Disqualifiers

None

Trial population

Patient with auto-immune encephalitis suspected and antibody characterized or not.

Trial design

Design model

Cohort

Time perspective

Cross-sectional

Treatments tested in this trial

  • Genetic and immunology tests

    Biological/Vaccine

    This is a non-interventional study involving clinical data and biological samples (blood, DNA, CSF, cells). Clinical data are collected for the center and samples are already stored in biobank repositories and collected as part of "good clinical practice" in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the "Centre de Ressources Biologiques des Hospices Civils de Lyon" (CRB-HCL) (including tissue, cells or biological fluids) and genetic analysis for research purposes.

Treatment groups

180 Participants
are divided into 3 treatment groups
Group A: Antibody characterized1 intervention
Group B: Atypical1 intervention
Group C: Without antibody1 intervention

Trial outcomes

Primary outcomes

1

Correlation between biological results and clinical data

This measure will compare the result of immunological and genetic makers with clinical data of each patient.

Time frame
Through study completion, an average of 1year

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.